These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16893647)

  • 1. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of benzamides and benzamidines: structural requirement of a pyrimidine ring for inhibition of EGFR tyrosine kinase.
    Asano T; Yoshikawa T; Nakamura H; Uehara Y; Yamamoto Y
    Bioorg Med Chem Lett; 2004 May; 14(9):2299-302. PubMed ID: 15081028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.
    Gaudette F; Raeppel S; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Macleod AR; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2010 Feb; 20(3):848-52. PubMed ID: 20071170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases.
    Asano T; Nakamura H; Uehara Y; Yamamoto Y
    Chembiochem; 2004 Apr; 5(4):483-90. PubMed ID: 15185372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenov VV; Milligan D
    Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
    Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases.
    Asano T; Yoshikawa T; Usui T; Yamamoto H; Yamamoto Y; Uehara Y; Nakamura H
    Bioorg Med Chem; 2004 Jul; 12(13):3529-42. PubMed ID: 15186837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Piatnitski EL; Samet AV; Kisliy VP; Semenov VV
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1369-75. PubMed ID: 17188873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
    Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors.
    Hamadeh HK; Todd M; Healy L; Meyer JT; Kwok AM; Higgins M; Afshari CA
    Chem Res Toxicol; 2010 Jun; 23(6):1025-33. PubMed ID: 20521778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
    Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.